Publication | Closed Access
Final survival and safety results from a multicenter, open‐label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer
27
Citations
10
References
2008
Year
No new safety signals were noted. The observed ORR and survival data are consistent with results from the pivotal trial BR.21.
| Year | Citations | |
|---|---|---|
Page 1
Page 1